CY1110389T1 - Χρηση του οξινου φουμαρικου r-(+)-2-(3-διισοπροπυλαμινο-1-φαινυλοπροπυλο)-4-υδροξυ-μεθυλο-φαινυλισοβουτυρικου εστερα για τη θεραπεια της επιτακτικης ακρατειας ουρων και αλλων σπασμογενων παθησεων - Google Patents

Χρηση του οξινου φουμαρικου r-(+)-2-(3-διισοπροπυλαμινο-1-φαινυλοπροπυλο)-4-υδροξυ-μεθυλο-φαινυλισοβουτυρικου εστερα για τη θεραπεια της επιτακτικης ακρατειας ουρων και αλλων σπασμογενων παθησεων

Info

Publication number
CY1110389T1
CY1110389T1 CY20081100712T CY081100712T CY1110389T1 CY 1110389 T1 CY1110389 T1 CY 1110389T1 CY 20081100712 T CY20081100712 T CY 20081100712T CY 081100712 T CY081100712 T CY 081100712T CY 1110389 T1 CY1110389 T1 CY 1110389T1
Authority
CY
Cyprus
Prior art keywords
diisopropylamino
hydroxy
fenylopropylo
fenylisobutyrta
espera
Prior art date
Application number
CY20081100712T
Other languages
English (en)
Inventor
Claus Meese
Original Assignee
Schwarz Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7929277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110389(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma Ag filed Critical Schwarz Pharma Ag
Publication of CY1110389T1 publication Critical patent/CY1110389T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Luminescent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

Χρήση του όξινου φουμαρικού R-(+)-2-(3-διισοπροπυλαμινο-1-φαινυλοπροπυλο)-4-υδροξυ-μεθυλο-φαινυλισοβουτυρικού εστέρα για τη θεραπεία της επιτακτικής ακράτειας ούρων και άλλων σπασμογενών παθήσεων.
CY20081100712T 1999-11-16 2008-07-08 Χρηση του οξινου φουμαρικου r-(+)-2-(3-διισοπροπυλαμινο-1-φαινυλοπροπυλο)-4-υδροξυ-μεθυλο-φαινυλισοβουτυρικου εστερα για τη θεραπεια της επιτακτικης ακρατειας ουρων και αλλων σπασμογενων παθησεων CY1110389T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19955190A DE19955190A1 (de) 1999-11-16 1999-11-16 Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
EP06011207A EP1690536B1 (de) 1999-11-16 2000-11-15 Verwendung von r-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxy-methyl-Phenylisobuttersäureester Hydrogenfumarat zur Behandlung von Harndrang-Inkontinenz und anderen spasmogenen Leiden

Publications (1)

Publication Number Publication Date
CY1110389T1 true CY1110389T1 (el) 2015-04-29

Family

ID=7929277

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061101493T CY1106204T1 (el) 1999-11-16 2006-10-18 Σταθepα αλατα καινοφανων παραγωγων 3,3-διφαινυλοπροπυλαμινων
CY20081100712T CY1110389T1 (el) 1999-11-16 2008-07-08 Χρηση του οξινου φουμαρικου r-(+)-2-(3-διισοπροπυλαμινο-1-φαινυλοπροπυλο)-4-υδροξυ-μεθυλο-φαινυλισοβουτυρικου εστερα για τη θεραπεια της επιτακτικης ακρατειας ουρων και αλλων σπασμογενων παθησεων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20061101493T CY1106204T1 (el) 1999-11-16 2006-10-18 Σταθepα αλατα καινοφανων παραγωγων 3,3-διφαινυλοπροπυλαμινων

Country Status (30)

Country Link
US (1) US6858650B1 (el)
EP (3) EP1690536B1 (el)
JP (6) JP4083431B2 (el)
KR (2) KR100563149B1 (el)
CN (1) CN1215045C (el)
AT (3) ATE286872T1 (el)
AU (1) AU778132B2 (el)
BR (1) BRPI0015610C1 (el)
CA (1) CA2389749C (el)
CY (2) CY1106204T1 (el)
CZ (2) CZ302967B6 (el)
DE (5) DE29923134U1 (el)
DK (3) DK1230209T3 (el)
EA (1) EA005588B1 (el)
ES (3) ES2270240T3 (el)
GE (1) GEP20084430B (el)
HK (3) HK1045148B (el)
HU (2) HU228197B1 (el)
IL (2) IL149567A0 (el)
IS (2) IS2124B (el)
MX (1) MXPA02004603A (el)
NO (2) NO323920B1 (el)
NZ (1) NZ519230A (el)
PL (1) PL201422B1 (el)
PT (3) PT1481964E (el)
SI (3) SI1690536T1 (el)
SK (3) SK287430B6 (el)
UA (2) UA73324C2 (el)
WO (1) WO2001035957A1 (el)
ZA (1) ZA200203315B (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
KR100647068B1 (ko) 2005-09-15 2006-11-23 하나제약 주식회사 라세믹ｎ,ｎ-디이소프로필-3-(2-히드록시-5-메틸페닐)-3-페닐프로판아민의 제조방법
DE602007009096D1 (de) * 2006-05-24 2010-10-21 Pfizer Ltd Verfahren zur herstellung von benzopyran-2-olderivaten
EP1862449A1 (en) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. A shortened synthesis of substituted hydroxymethyl phenols
EA016399B1 (ru) * 2006-05-31 2012-04-30 Шварц Фарма Лтд. Способ синтеза замещенных гидроксиметилфенолов
IES20060424A2 (en) 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
WO2007140986A1 (en) * 2006-06-09 2007-12-13 Schwarz Pharma Ltd Synthesis of phenolic esters of hydroxymethyl phenols
PL2029134T3 (pl) 2006-06-09 2011-12-30 Ucb Pharma Gmbh Stabilizowane kompozycje farmaceutyczne zawierające fezoterodynę
US7807715B2 (en) 2006-06-09 2010-10-05 Ucb Pharma Gmbh Pharmaceutical compositions comprising fesoterodine
AU2007260267B2 (en) * 2006-06-12 2012-09-06 Ucb Pharma Gmbh New chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof
IES20060435A2 (en) 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
US20100217034A1 (en) * 2007-09-21 2010-08-26 Actavis Group Ptc Ehf Process for the Preparation of Fesoterodine
US20100297241A1 (en) * 2007-10-01 2010-11-25 Actavis Group Ptc Ehf Amorphous Fesoterodine Fumarate
EP2294047A2 (en) * 2008-04-04 2011-03-16 Actavis Group PTC EHF Novel mandelate salt of fesoterodine
US20110171274A1 (en) * 2008-07-21 2011-07-14 Actavis Group Ptc Ehf Fesoterodine Substantially Free of Dehydroxy Impurity
IT1392082B1 (it) * 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
ES2533956T3 (es) 2009-05-11 2015-04-16 Ratiopharm Gmbh Desfesoterodina en forma de una sal de ácido tartárico
IT1394217B1 (it) * 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
IT1394219B1 (it) * 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.
WO2011029005A1 (en) 2009-09-03 2011-03-10 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline forms of fesoterodine fumarate and fesoterodine base
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20110124903A1 (en) * 2009-11-20 2011-05-26 Actavis Group Ptc Ehf Solid state forms of fesoterodine intermediates
IT1397521B1 (it) * 2009-12-21 2013-01-16 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina con un basso contenuto di impurezze.
IT1397920B1 (it) * 2010-02-08 2013-02-04 Dipharma Francis Srl Forma cristallina di fesoterodina fumarato e procedimento per la sua preparazione
US20130172411A1 (en) 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
EP2563123B1 (en) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
WO2011141932A2 (en) 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
WO2011145019A1 (en) * 2010-05-17 2011-11-24 Orchid Chemicals And Pharmaceuticals Limited Improved process for diphenylpropylamine derivatives
IT1401451B1 (it) 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
WO2011158257A1 (en) 2010-06-18 2011-12-22 Panacea Biotec Ltd Preparation process of fesoterodine and intermediates
WO2012025941A2 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Processes for the preparation of fesoterodine
IT1403094B1 (it) 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
WO2012098560A2 (en) * 2011-01-17 2012-07-26 Msn Laboratories Limited Process for the preparation of muscarinic receptor antagonist
TWI520732B (zh) 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
JP6234999B2 (ja) 2012-05-04 2017-11-22 クリスタル ファルマ、エセ、ア、ウＣｒｙｓｔａｌ Ｐｈａｒｍａ，Ｓ．Ａ．Ｕ． 光学的に活性な３，３−ジフェニルプロピルアミンを調製するための方法
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
TR201721437A2 (tr) 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
EP4237405A1 (en) * 2020-10-27 2023-09-06 Wella Germany GmbH 2-methoxymethyl-p-phenylenediamine in cosmetic grade quality

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA817863B (en) * 1980-11-14 1983-06-29 Lilly Co Eli (-)n-methyl-3-(2-methylphenoxy)-3-phenylpropylamnie,antidepressant
IL66831A0 (en) * 1981-10-05 1982-12-31 Kefalas As Indane derivatives
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
EP0445749B1 (en) * 1990-03-08 1996-07-10 Fujisawa Pharmaceutical Co., Ltd. N-Monosubstituted cyclopentenylamines, a process for their preparation and their use as medicaments
JPH0483431A (ja) * 1990-07-26 1992-03-17 Seiko Epson Corp 選択呼出受信機
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen

Also Published As

Publication number Publication date
EA005588B1 (ru) 2005-04-28
KR100536095B1 (ko) 2005-12-12
DK1481964T3 (da) 2006-11-27
EA200200511A1 (ru) 2002-10-31
MXPA02004603A (es) 2004-09-10
BRPI0015610C1 (pt) 2021-05-25
HK1067114A1 (en) 2005-04-01
WO2001035957A8 (de) 2001-06-21
CZ20021343A3 (cs) 2002-09-11
UA73324C2 (uk) 2005-07-15
BR0015610A (pt) 2002-07-30
NO20065380L (no) 2002-05-15
JP2014111589A (ja) 2014-06-19
JP4083431B2 (ja) 2008-04-30
IL149567A0 (en) 2002-11-10
NO332637B1 (no) 2012-11-26
HK1045148B (zh) 2005-05-06
EP1690536A2 (de) 2006-08-16
DE50015163D1 (de) 2008-06-26
AU2666701A (en) 2001-05-30
HU228197B1 (en) 2013-01-28
JP2010180242A (ja) 2010-08-19
SI1481964T1 (sl) 2006-12-31
CZ302967B6 (cs) 2012-01-25
JP5290351B2 (ja) 2013-09-18
JP5717824B2 (ja) 2015-05-13
CA2389749C (en) 2009-03-31
US6858650B1 (en) 2005-02-22
ES2236032T3 (es) 2005-07-16
HUP0204034A2 (hu) 2003-03-28
AU778132B2 (en) 2004-11-18
ES2270240T3 (es) 2007-04-01
JP2007137895A (ja) 2007-06-07
UA77322C2 (en) 2006-11-15
CA2389749A1 (en) 2001-05-25
ES2303708T3 (es) 2008-08-16
HUP0204034A3 (en) 2004-12-28
EP1481964B1 (de) 2006-08-23
SI1230209T1 (en) 2005-06-30
SI1690536T1 (sl) 2008-08-31
ATE286872T1 (de) 2005-01-15
EP1481964A1 (de) 2004-12-01
DE19955190A1 (de) 2001-06-21
ES2236032T7 (es) 2012-06-14
PT1481964E (pt) 2006-12-29
SK6572002A3 (en) 2002-12-03
EP1690536B1 (de) 2008-05-14
SK288185B6 (sk) 2014-04-02
CY1106204T1 (el) 2011-06-08
NO20022314L (no) 2002-05-15
BR0015610B8 (pt) 2017-10-31
IS2124B (is) 2006-07-14
CZ302497B6 (cs) 2011-06-15
WO2001035957A3 (de) 2001-12-27
HK1095736A1 (en) 2007-05-18
DE29923134U1 (de) 2000-06-29
JP5650924B2 (ja) 2015-01-07
JP2010180243A (ja) 2010-08-19
PL356766A1 (en) 2004-07-12
SK288384B6 (sk) 2016-08-01
HK1045148A1 (en) 2002-11-15
EP1230209B1 (de) 2005-01-12
EP1690536A3 (de) 2006-08-23
IS8382A (is) 2006-03-29
CN1390194A (zh) 2003-01-08
JP2011148824A (ja) 2011-08-04
BRPI0015610B1 (pt) 2016-04-19
WO2001035957A1 (de) 2001-05-25
DE50013365D1 (de) 2006-10-05
IS6351A (is) 2002-04-19
ATE395056T1 (de) 2008-05-15
DK1690536T3 (da) 2008-09-01
EP1230209B3 (de) 2011-10-05
PT1690536E (pt) 2008-07-14
KR20020059744A (ko) 2002-07-13
HU0900587D0 (en) 2009-11-30
NO20022314D0 (no) 2002-05-15
JP2003514018A (ja) 2003-04-15
ATE337293T1 (de) 2006-09-15
CN1215045C (zh) 2005-08-17
EP1230209A2 (de) 2002-08-14
JP5503393B2 (ja) 2014-05-28
GEP20084430B (el) 2008-07-25
KR20050100711A (ko) 2005-10-19
SK287430B6 (sk) 2010-09-07
DE50009239D1 (de) 2005-02-17
PT1230209E (pt) 2005-05-31
IL149567A (en) 2007-08-19
DK1230209T3 (da) 2005-05-30
HUP0900587A3 (en) 2010-04-28
ZA200203315B (en) 2003-09-23
IS2673B (is) 2010-09-15
KR100563149B1 (ko) 2006-03-21
PL201422B1 (pl) 2009-04-30
NO323920B1 (no) 2007-07-23
NZ519230A (en) 2004-11-26
HU227608B1 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
CY1110389T1 (el) Χρηση του οξινου φουμαρικου r-(+)-2-(3-διισοπροπυλαμινο-1-φαινυλοπροπυλο)-4-υδροξυ-μεθυλο-φαινυλισοβουτυρικου εστερα για τη θεραπεια της επιτακτικης ακρατειας ουρων και αλλων σπασμογενων παθησεων
EE04416B1 (et) a1L- agonistide kasutamine uriiniinkontinentsuse raviks
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
CY2009002I2 (el) Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
AU2001275257A1 (en) Methods and devices for the treatment of urinary incontinence
DK0778749T3 (da) Kirurgisk instrument til behandling af urininkontinens hos kvinder
DK1390049T3 (da) Sammensætninger til behandling af dyresygdomme og -syndromer omfattende transferfaktor
MXPA03005769A (es) Politrimetilen eter ester amida y uso de la misma.
DE60039415D1 (de) Reovirus zur behandlung von zellulären proliferativen erkrankungen
DE60233825D1 (de) BENZOATESÄURE-2-(a-HYDROXYPENTYL)ESTER UND DESSEN HERSTELLUNG UND VERWENDUNG
DE60011540D1 (de) Verfahren zur Desinfektion von Kontaktlinsen
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
PL364465A1 (en) Use of selective cox-2 inhibitors for the treatment of urinary incontinence
DE60020681D1 (de) Zusammensetzungen und verfahren zur verbesserung der integrität von angegriffenen körperpassagewegen und höhlen
AU2003214273A8 (en) Improved system for the treatment of stress urinary incontinence
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
AUPQ968700A0 (en) Treatment of urinary incontinence
NO20005548L (no) Mykobakterieinhibitorer
CO5210863A1 (es) Medicamento para el tratamiento de urgencia urinaria incre- mentada o incontinencia urinaria . . . . .
AU2002360696A1 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
GB9922710D0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
NO20012569D0 (no) Anvendelse av aryl-substituerte syklobutylaminer for behandling av urininkontinens
IL162776A0 (en) 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
ATE293966T1 (de) Verwendung von 2-amino-1-(4-hydroxy-3- methanesulphonamidophenyl)ethanol zur behandlung von harninkontinenz
IT241277Y1 (it) Assorbente adesivo per piccola incontinenza urinaria maschile